Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MLYCD | O95822 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1304440 | 0.74 | PDE10A (0.41) | SMN1; SMN2ALDH1A1HPGDMLYCDGPR119 | |
| SCHEMBL1303598 | 0.73 | HPGD (0.44) | SMN1; SMN2ALDH1A1HPGDMLYCDGPR119 | |
| SCHEMBL13296428 | 0.68 | MAPT (0.40) | SMN1; SMN2ALDH1A1NPC1RAB9APDE10A | |
| SCHEMBL19533698 | 0.64 | SMN1; SMN2 (0.59) | SMN1; SMN2ALDH1A1HPGDMLYCDNPC1 | |
| SCHEMBL28237 | 0.63 | KDM4E (0.53) | SMN1; SMN2ALDH1A1HPGDMLYCDMMP13 | |
| SCHEMBL286256 | 0.63 | CES2 (0.57) | SMN1; SMN2ALDH1A1HPGDMLYCD | |
| SCHEMBL1012521 | 0.61 | MLYCD (0.57) | SMN1; SMN2ALDH1A1HPGDMLYCDNPC1 | |
| SCHEMBL24107482 | 0.61 | CA1 (0.44) | ALDH1A1 | |
| SCHEMBL4654242 | 0.60 | MLYCD (0.60) | SMN1; SMN2ALDH1A1HPGDMLYCDGPR119 | |
| SCHEMBL17758796 | 0.60 | MLYCD (0.49) | SMN1; SMN2ALDH1A1HPGDMLYCDGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329700-B2 | Pyrazine compounds as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329700-B2 | Pyrazine compounds as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329700-B2 | Pyrazine compounds as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120277209-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277209-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277209-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2012-11-01 | — | — | US | disclosed |
| EP-2364308-B1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC (US) | 2012-10-24 | — | — | EP | disclosed |
| EP-2364308-B1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC (US) | 2012-10-24 | — | — | EP | disclosed |
| US-8247418-B2 | Pyrazine compounds as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247418-B2 | Pyrazine compounds as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20110160202-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160182-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160182-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160182-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160202-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20100137278-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137278-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137278-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| WO-2010057121-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010057121-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160182-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | PDE10A, PDE12, PDE5A | SMN1; SMN2 4522/4885ALDH1A1 929/4885HPGD 857/4885 |
| US-20100137278-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | PDE10A, PDE12, PDE5A | SMN1; SMN2 4522/4885ALDH1A1 929/4885HPGD 857/4885 |
| US-20110160202-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | PDE10A, PDE12, PDE5A | SMN1; SMN2 4522/4885ALDH1A1 929/4885HPGD 857/4885 |
| US-20120277209-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | PDE10A, PDE12, PDE5A | SMN1; SMN2 3861/4885ALDH1A1 1799/4885HPGD 1933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.